Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer

Annals of Oncology

Volumn 18, Issue 5, 2007, Pages 898-902

  Ilson, D H ^a,d   Wadleigh, R G ^b   Leichman, L P ^c,e   Kelsen, D P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Eisenhower Medical Center ^*  (United States)

^e EISENHOWER MEDICAL CENTER   (United States)

Author keywords

Adenocarcinoma; Esophageal cancer; Squamous cell carcinoma; Weekly paclitaxel

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; FEMALE; FOOT DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUROPATHY; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARTHRALGIA; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 34447323322     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm004     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998; 83: 2049-2053.
3. Muller JM, Erasmi H, Stelzner M et al. Surgical therapy of oesophageal carcinoma. Br J Surg 1990; 77: 845-857.
4. Kelsen DP, Ginsberg R, Pajak TF et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med 1998; 339: 1979-1984
5. Ajani J, Ilson D, Daugherty K et al. Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994; 86: 1086-1091.
6. Ilson DH, Ajani J, Bhalla K et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998; 16: 1826-1834.
7. Ilson DH, Forastiere A, Arquette M et al. A phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the esophagus. Cancer J 2000; 6: 316-323.
8. Adelstein D, Rice TW, Rybicki LA et al. Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000; 18: 2032-2039.
9. Wright CD, Wain JC, Lynch TJ et al. Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: A phase I and II study. J Thorac Cardiovasc Surg 1997; 114: 811-815.
10. Meluch AA, Hainsworth JD, Gray JR et al. Preoperative combined modality therapy with paclitaxel carboplatin, prolonged infusion 5 fluorouracil, and radiation therapy in localized esophageal cancer: Preliminary results of a Minnie Pearl Cancer Research Network phase II trial. Cancer J Sci Am 1999; 5: 84-91.
11. Fennelly D, Aghajanian C, Shapiro F et al Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997; 15: 187-192.
12. Abu-Rustum NR, Aghajanian C, Barakat RR et al. Salvage weekly paclitaxel in recurrent ovarian cancer. Semin Oncol 1997; 24 (Suppl 15): 62-67.
13. Seidman AD, Hudis CA, Albanel J et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16: 3353-3361.
14. Perez EA, Vogel CL, Irwin DH et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001; 19: 4216-4223.
15. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
16. Muro K, Hamaguchi T, Ohtsu A et al. A phase II study of single agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004; 15: 955-959.
17. Heath E, Urba S, Marshall J et al. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 2002; 20: 95-99.
18. Li-Shin Lin L, Hecht JR. A phase II trial of irinotecan in patients with advanced adenocarcinoma of the gastroesophageal (GE) junction. Proc Am Soc Clin Oncol 2000; 18: 289 (Abstr 1130).
19. Enzinger PC, Kulke MH, Clark JW et al. Phase II trial of CPT-11 in previously untreated patients with advanced adenocarcinoma of the esophagus and stomach. Proc Am Soc Clin Oncol 2000; 19: 315 (Abstr 1243).
20. Conroy T, Etienne PL, Adonis A et al. Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. J Clin Oncol 1996; 4: 164-170
21. Brenner B, Ilson D, Minsky B et al. Phase I trial of combined-modality therapy for localized esophageal cancer: Escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004; 22: 45-52.
22. Safran H, Gaissert H, Akerman P et al. Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001; 19: 1-7.
23. Bains M, Stojadinovic A, Minsky B et al. A Phase II trial of preoperative combined modality therapy for localized esophageal carcinoma: Initial results. J Thorac Cardiovasc Surg 2002; 124: 270-277.
24. Urba S, Orringer M, Iannettoni M et al. Concurrent cisplatin, paclitaxel, and radiotherapy as preoperative treatment for patients with locoregional esophageal cancer. Cancer 2003; 98: 2177-2183.
25. Lin CC, Hsu CH, Cheng JC et al. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol 2007; 18: 93-98.
26. van Meerten E, Muller K, Tilanus HW et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with esophageal cancer: A phase II study. Br J Cancer 2006; 94: 1389-1394.
27. Suntharalingham M, Dipetrillo T, Akerman P et al. Cetuximab, paclitaxel, carboplatin, and radiation for esophageal and gastric cancer. J Clin Oncol 2006; 24 (18S): 4029.
28. Ajani J, Walsh G, Komaki R et al. Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. Cancer 2004; 100: 2347-2354.